<DOC>
	<DOC>NCT01451450</DOC>
	<brief_summary>This study will assess the clinical potency of several exposure levels of QGE031 in decreasing the sensitivity against peanut allergen.</brief_summary>
	<brief_title>Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<criteria>Main Diagnosis of acute peanut allergy as manifested by urticaria, angioedema, gastrointestinal or respiratory tract symptoms, with acute onset of symptoms after ingestion (up to 2 hours). Positive peanut food challenge at baseline, i.e., have objective allergic events at a level of 300mg (not cumulative) or below of peanut protein but not to the placebo test. Main Prior exposure to any monoclonal antibody treatment Asthma patients on maintenance long acting betaagonists Use of systemic corticosteroids Concomitant use of beta blockers, ACE inhibitors, tiotropium or ipratropium, antidepressants, oral betaagonists Use of immunosuppressants within 6 months of visit 1 Other protocoldefined inclusion/exclusion criteria may appy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Peanut Allergy</keyword>
</DOC>